CN1617737A - 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 - Google Patents

用于使哺乳动物组织中的脂质水平正常化的组合物和方法 Download PDF

Info

Publication number
CN1617737A
CN1617737A CNA028275691A CN02827569A CN1617737A CN 1617737 A CN1617737 A CN 1617737A CN A028275691 A CNA028275691 A CN A028275691A CN 02827569 A CN02827569 A CN 02827569A CN 1617737 A CN1617737 A CN 1617737A
Authority
CN
China
Prior art keywords
cgrp
receptor
lipid
amylopectin
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028275691A
Other languages
English (en)
Chinese (zh)
Inventor
G·J·S·库珀
K·M·卢米斯
R·N·沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PUROTMIX Ltd
Protemix Corp Ltd
Original Assignee
PUROTMIX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PUROTMIX Ltd filed Critical PUROTMIX Ltd
Publication of CN1617737A publication Critical patent/CN1617737A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
CNA028275691A 2001-11-26 2002-11-26 用于使哺乳动物组织中的脂质水平正常化的组合物和方法 Pending CN1617737A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33342201P 2001-11-26 2001-11-26
NZ515731 2001-11-26
US60/333,422 2001-11-26
NZ51573101 2001-11-26

Publications (1)

Publication Number Publication Date
CN1617737A true CN1617737A (zh) 2005-05-18

Family

ID=26652295

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028275691A Pending CN1617737A (zh) 2001-11-26 2002-11-26 用于使哺乳动物组织中的脂质水平正常化的组合物和方法

Country Status (6)

Country Link
EP (1) EP1461068A4 (fr)
JP (1) JP2005523418A (fr)
CN (1) CN1617737A (fr)
AU (2) AU2002356469A1 (fr)
CA (1) CA2471833A1 (fr)
WO (1) WO2003045424A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018392A1 (fr) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine-oxydase: antagonistes et inhibiteurs
EP2500018B1 (fr) 2002-03-08 2017-07-19 PhilERA New Zealand Limited Prévention et/ou traitement des maladies cardio-vasculaires et/ou insuffisances cardiaques associées
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
CA2875095C (fr) 2004-07-19 2019-09-03 Philera New Zealand Limited Synthese de triethylenetetramines
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
HUE054437T2 (hu) 2011-05-20 2021-09-28 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP2709663B1 (fr) 2011-05-20 2019-03-20 AlderBio Holdings LLC Utilisation d'anticorps et de fragments d'anticorps anti-cgrp dans la prévention ou l'inhibition de la photophobie ou de l'aversion à la lumière chez des sujets qui en ont besoin, en particulier des personnes souffrant de migraines
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
EP3908606A4 (fr) 2019-01-08 2022-11-23 H. Lundbeck A/S Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
AU6524794A (en) * 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
WO1996005221A1 (fr) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Recepteur de calcitonine
WO1998003534A1 (fr) * 1996-07-23 1998-01-29 Smithkline Beecham Corporation Facteur composant du recepteur du peptide apparente au gene de la calcitonine (houdc44)
CN1055640C (zh) 1996-11-29 2000-08-23 沃维汉 人降钙素基因相关肽脂质体组合物及其制法
ES2356595T3 (es) * 1998-02-13 2011-04-11 Amylin Pharmaceuticals, Inc. Nuevos compuestos de actividad mixta de la amilina.

Also Published As

Publication number Publication date
EP1461068A1 (fr) 2004-09-29
AU2009201147A1 (en) 2009-04-23
AU2002356469A2 (en) 2003-06-10
CA2471833A1 (fr) 2003-06-05
AU2002356469A1 (en) 2003-06-10
EP1461068A4 (fr) 2006-03-29
WO2003045424A1 (fr) 2003-06-05
JP2005523418A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
CN1305897C (zh) 新肽化合物和其制备方法及含有它们的药物组合物
CN1238367C (zh) 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
CN1048731C (zh) 编码细胞因子抑制性抗炎药物结合蛋白质的多核苷酸
CN1789411A (zh) 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
CN1916167A (zh) 过氧化物酶体增殖物激活受体的调节
CN1886423A (zh) 脂联素的糖基同工型及其用途
CN1960758A (zh) 关节炎的治疗剂或预防剂
CN1176947C (zh) 用于治疗骨质疏松症的甲状旁腺激素类似物
CN1636058A (zh) 新型丙氨酸转氨酶及其应用方法
CN1884521A (zh) 发现新基因的方法和使用的计算机系统平台以及新基因
CN1617737A (zh) 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
CN1276254C (zh) 筛选实验化合物的测定方法和试剂盒
CN1796558A (zh) 分离的编码t细胞诱导因子或白介素－21的核酸分子,其编码的蛋白和其应用
CN1543350A (zh) 糖半抗原和聚集的蛋白载体的免疫原性结合物
CN1633506A (zh) 鉴定5－脂氧化酶作为引起动脉硬化症的主要基因
CN1216900C (zh) 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽
CN1307989C (zh) 植烷酸在制备治疗糖尿病的药物中的用途
CN1878865A (zh) 无细胞Notch切割分析方法以及药物筛选方法
CN1296384C (zh) 具有preptin功能的肽
CN1850269A (zh) Gpr39基因在哺乳动物中枢神经系统的功能及其应用
CN1211486C (zh) 编码前神经肽y原突变体,一种信号肽的突变体,的dna分子及其应用
CN1697878A (zh) 具有cAMP生成活性的新肽
CN1950103A (zh) 骨疾病的预防或治疗方法
CN1927888A (zh) Glp－1及其类似物与人溶菌酶融合的重组蛋白及其用途
CN1541335A (zh) Epf受体测定,化合物和治疗组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication